Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Affimed NV

AFMD
Current price
5.15 USD +0.02 USD (+0.39%)
Last closed 5.07 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 87 558 128 USD
Yield for 12 month +532.68 %
1Y
3Y
5Y
10Y
15Y
AFMD
21.11.2021 - 28.11.2021

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Address: Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

22.35 USD

P/E ratio

Dividend Yield

Current Year

+8 786 730 USD

Last Year

+43 910 291 USD

Current Quarter

+438 540 USD

Last Quarter

+2 083 331 USD

Current Year

+8 786 730 USD

Last Year

+43 910 291 USD

Current Quarter

+438 540 USD

Last Quarter

+2 083 331 USD

Key Figures AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -102 586 000 USD
Operating Margin TTM -382.46 %
PE Ratio
Return On Assets TTM -43.5 %
PEG Ratio
Return On Equity TTM -100.55 %
Wall Street Target Price 22.35 USD
Revenue TTM 13 914 000 USD
Book Value 3.85 USD
Revenue Per Share TTM 0.93 USD
Dividend Share
Quarterly Revenue Growth YOY -58.3 %
Dividend Yield
Gross Profit TTM 42 869 000 USD
Earnings Share -7.62 USD
Diluted Eps TTM -7.62 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AFMD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 11.03.2024
Dividend Date

Stock Valuation AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 3.64
Price Sales TTM 6.2928
Enterprise Value EBITDA -0.2942
Price Book MRQ 1.4102

Financials AFMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AFMD

For 52 weeks

2.24 USD 11.1 USD
50 Day MA 5.66 USD
Shares Short Prior Month 171 633
200 Day MA 5.18 USD
Short Ratio 1.65
Shares Short 196 431
Short Percent 1.37 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics